PGS ASA: Implementation of 2023 Employee Long-term Incentive Plan
May 22, 2023, Oslo, Norway: PGS (or the "Company") announces that the 2023 long term incentive plan, as approved by the Annual General Meeting on April 26, 2023, has now been implemented by allocating 4 639 000 Performance based Restricted Stock Units ("PRSUs").
The awards are based on amongst other considerations the position in the Company and a review on the individual participant's performance prior to award. Any PRSU awarded will, subject to the participant's continued employment with the Company (or a subsidiary), be settled three years after grant. The complete terms and conditions of the award are described in the calling notice for the 2023 Annual General Meeting.
Delivery of shares will take place from the Company's pool of treasury shares or, if an insufficient number of treasury shares exist, it will be settled by cash payment of an equivalent value.
The purpose of the long-term incentive plan is to further the interests of PGS, its subsidiaries and its shareholders to employees who can contribute materially to the success and profitability of PGS. Such awards will recognize and reward performance and individual contributions and give participants in the plan an interest in the Company parallel to that of the shareholders, thus enhancing the proprietary and personal interest in PGS' continued success and progress.
The Board of Directors has allocated PRSUs according to the plan to the following primary insiders in PGS:
Rune Olav Pedersen, President & CEO, has been awarded 329 000 PRSUs in the Company. Following the award, Pedersen holds 644 365 shares in PGS and 1 386 000 PRSUs.
Gottfred Langseth, Executive Vice President & CFO, has been awarded 140 000 PRSUs in the Company. Following the award, Langseth holds 1 268 297 shares in PGS and 586 000 PRSUs.
Nathan Oliver, Executive Vice President Sales & Services, has been awarded 140 000 PRSUs in the Company. Following the award, Oliver holds 15 000 shares in PGS and 586 000 PRSUs.
Robert J. Adams, Executive Vice President Operations, has been awarded 140 000 PRSUs in the Company. Following the award, Adams holds 16 126 shares in PGS and 586 000 PRSUs.
Berit Osnes, Executive Vice President New Energy, has been awarded 140 000 PRSUs in the Company. Following the award, Osnes holds 54 377 shares in PGS, 455 000 PRSUs.
Erik Ewig, Senior Vice President Technology & Digitalization, has been awarded 140 000 PRSUs in the Company. Following the award, Ewig holds 7 391 shares in PGS and 420 000 PRSUs
Lars Ragnar Mysen, General Counsel, has been awarded 50 000 PRSUs in the Company. Following the award, Mysen holds 202 306 shares in PGS and 213 000 PRSUs.
Kristin Omreng, Senior Vice President Global HR, has been awarded 50 000 PRSUs in the Company. Following the award, Omreng holds 20 000 shares in PGS and 213 000 PRSUs.
Kai Reith, Senior Vice President Corporate Development, has been awarded 50 000 PRSUs in the Company. Following the award, Reith holds 90 647 shares in PGS and 213 000 PRSUs.
Bård Stenberg, Vice President IR & Corporate Communications, has been awarded 50 000 PRSUs in the Company. Following the award, Stenberg holds 26 000 shares in PGS and 210 000 PRSUs.
Anette Valbø, employee elected Board Member and Bidding Manager, has been awarded 10 500 PRSUs in the Company. Following the award, Valbø holds 13 354 shares in PGS and 44 000 PRSUs.
Eivind Vesterås, employee elected Board Member and Special Projects Manager, has been awarded 10 500 PRSUs in the Company. Following the award, Vesterås holds 158 500 shares in PGS and 38 500 PRSUs.
Carine Roalkvam, employee elected Board Member and Regional Geophysical Advisor & Geophysical Support Manager, has been awarded 15 000 PRSUs in the Company. Following the award, Roalkvam holds 970 shares in PGS and 63 000 PRSUs.
Gunhild Myhr, employee elected alternate Board Member and Business Development Manager, has been awarded 30 000 PRSUs in the Company. Following the award, Myhr holds 1 940 shares in PGS and 79 500 PRSUs.
Merethe Bryn, employee elected alternate Board Member and VP Global Tax, has been awarded 30 000 PRSUs in the Company. Following the award, Bryn holds 12 427 shares in PGS and 134 000 PRSUs
Christopher Watts, employee elected alternate Board Member and VP Sales & Services, has been awarded 23 000 PRSUs in the Company. Following the award, Watts holds 0 shares in PGS and 97 000 PRSUs.
Further details on remuneration of management are described in PGS’ 2022 annual report.
This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Mowi ASA (OSE: MOWI): 2023 Salmon Farming Industry Handbook9.6.2023 06:30:00 CEST | Press release
Please find attached the 2023 version of the Salmon Farming Industry Handbook. The handbook is also available on our website www.mowi.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment 2023 Salmon Farming Industry Handbook
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor